CONDITION

Steroid-Responsive Meningitis-Arteritis (SRMA)

Why this matters now

SRMA most commonly affects young dogs between 6 months and 2 years of age, though it can occasionally occur in older dogs. The acute form often presents suddenly, with dogs appearing severely unwell within a short period.

Without appropriate treatment, the acute form can progress or relapse into a chronic form with ongoing low-grade inflammation. Early recognition and treatment typically leads to good outcomes, though relapses can occur during treatment tapering. Some dogs require prolonged management to prevent recurrence.

Signals & patterns

Early signals

Neck stiffness and reluctance to move

Affected dogs often hold their head low and resist bending their neck, showing obvious discomfort with movement.

Fever

Dogs frequently develop high temperatures, often feeling warm to the touch.

Hunched posture

Dogs may adopt a rigid, arched stance suggesting spinal discomfort.

Lethargy and depression

Affected dogs typically appear dull, reluctant to engage, and less responsive than normal.

Later signals

Severe pain on neck manipulation

Any attempt to move the head or neck may provoke yelping or aggression due to pain.

Difficulty rising

The combination of pain and stiffness can make getting up from lying extremely difficult.

Complete reluctance to eat

Pain may prevent dogs from lowering their head to food bowls.

Neurological signs

In some cases, particularly chronic forms, weakness or coordination problems may develop.

Click to read about the biological mechanisms

How this is usually investigated

Diagnosis of SRMA typically involves analysis of cerebrospinal fluid alongside blood tests and imaging to rule out other causes of meningitis.

Cerebrospinal fluid analysis

Purpose: CSF tap reveals characteristic changes including elevated white blood cell counts (particularly neutrophils) and raised protein.
Considerations: Requires sedation or anaesthesia. The procedure carries small risks but provides essential diagnostic information.

Blood tests

Purpose: Typically show elevated white blood cell count and inflammatory markers. IgA levels may be elevated.
Considerations: While supportive, blood changes alone are not specific to SRMA.

MRI

Purpose: Can reveal meningeal enhancement and rule out other structural causes such as disc disease or tumours.
Considerations: Requires general anaesthesia. Not always necessary if CSF analysis is definitive.

Infectious disease testing

Purpose: Rules out infectious causes of meningitis that would require different treatment.
Considerations: Important to exclude before starting immunosuppressive therapy.

Options & trade-offs

Treatment centres on immunosuppression to control the aberrant immune response, typically requiring prolonged courses with careful monitoring.

Corticosteroid therapy

High-dose steroids are typically used initially, then gradually tapered over months as inflammation resolves.

Trade-offs: Steroid side effects include increased thirst, urination, appetite, and potential behavioural changes. Premature dose reduction risks relapse.

Additional immunosuppressants

Drugs such as azathioprine or mycophenolate may be used alongside steroids in some cases.

Trade-offs: Additional monitoring requirements and potential side effects. May allow lower steroid doses.

Pain management

Analgesics may be used initially to improve comfort while waiting for immunosuppression to take effect.

Trade-offs: Provides symptomatic relief but does not address underlying inflammation.

Monitoring protocols

Regular rechecks including repeat CSF analysis may be used to guide treatment duration.

Trade-offs: Involves repeated procedures and costs but helps optimise treatment length.

Common misconceptions

Misconception:

"SRMA is caused by an infection that needs antibiotics."

Reality:

SRMA is immune-mediated, not infectious. While infection must be ruled out, the treatment is immunosuppression rather than antibiotics.

Misconception:

"Once symptoms resolve, treatment can stop."

Reality:

Premature treatment cessation is a common cause of relapse. Most protocols involve gradual tapering over many months.

Misconception:

"SRMA always causes permanent neurological damage."

Reality:

With prompt, appropriate treatment, most dogs recover fully. The condition responds well to immunosuppression in the majority of cases.

Understanding the typical age and breed predispositions for SRMA can help in recognising the condition. Learning about the treatment commitment involved, including the duration and monitoring requirements, provides useful context. Noting any episodes of neck pain, stiffness, or fever to share with your veterinary team may assist in their assessment.

Last reviewed: 24 April 2026 · Dr Alastair Greenway MRCVS